A Chinese Multi-Center,Randomized Study of Combination or Sequential Use of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy for Node Positive Breast Cancer
In this national wide study, women with node positive operable breast cancer are eligible
for inclusion.Patients were designed to randomize to six cycles of adjuvant TAC (Taxotere®
75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2), and four
cycles of T(100mg/m2), followed by 4 cycles of AC(doxorubicin 60mg/m2 or epirubicin 75mg/m2
,cyclophosphamide 600mg/m2). Prophylaxis with G-CSF was allowed for two arms when febrile
neutropenia occurred in the first cycle of the study treatment. The second endpoint of this
study is disease free survival. The primary objective is to compare the disease free
survival rate and safety profiles of the above mentioned two arms.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease Free Survival
5 years and 10 years
Zhenzhou Shen, M.D.
Cancer Hospital / Institute, Fudan University
China:Chinese Breast Cancer Society,Chinese Anti-Cancer Association